KRAS and non-small cell lung carcinoma: Sotorasib was the first FDA-approved drug for patients with non-small cell lung cancer (NSCLC) characterized by the presence of the KRAS G12C mutation, if they received or underwent prior systemic therapy (NCT03600883) [38].